Additional Information

This CME activity was developed for oncologists and other medical professionals who assess, counsel, and treat lung cancer patients.

Program Faculty
Thomas J. Lynch, Jr. , MD Chief Oncology/ Hematology, MGH Cancer Center; Rebecca S. Heist, MD, MPH, Department of Oncology, MGH Cancer Center, Tracey L. Evans, MD, Department of Medicine, University of Pennsylvania School of Medicine, Mark A. Socinski, MD, Program Director, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, Emer Hanrahan, MD, and Edward S. Kim, MD, Department of Medicine, The University of Texas MD Anderson Cancer Center.

The CME activity is no longer active.

Statement of Need
Medical professionals who treat lung cancer patients must understand why angiogenesis and VEGF are important targets in lung cancer and be able to assess clinical data for anti-VEGF agents, as well as opportunities and issues related to the integration of these agents into current practice.

Educational Grant Support
Supported by an educational grant from Genentech.

Sponsorship
CME sponsorship was provided by InforMEDical Communications, Inc.